Phase II trials planned for oral methylnaltrexone for chronic pain

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 11
Volume 16
Issue 11

Phase II trials planned for oral methylnaltrexone for chronic pain

COLLEGEVILLE, Pennsylvania—Wyeth Pharmaceuticals and Progenics plan to initiate two 4-week phase II clinical trials to evaluate daily dosing of oral methylnaltrexone in patients with chronic, nonmalignant pain who are experiencing opioid-induced constipation (OIC). An NDA for the subcutaneous formulation has been filed with FDA for the treatment of OIC in the end-of-life setting.

Articles in this issue
MT103, BiTE antibody, enters phase II testing for ALL
Sides dig in as ESA policy debate heats up
Ixempra gets ok for resistant breast cancer
ASCO adds Oncotype DX to marker guideline
Dr. Norton hopes to weed 'molecular' tumor garden
Accelerated approval for Tasigna
Oxidative stress inducer ups survival in advanced melanoma
FDA removes partial hold on Telcyta clinical development
Should all HER2+ pts receive adjuvant trastuzumab?
R-CHOP is standard of care for advanced DLBCL patients
FDA oks Velcade for patients with renal dysfunction
Phase II trials planned for oral methylnaltrexone for chronic pain
GSK and Synta announce STA-4783 collaboration
2007: A tumultuous year for erythropoietic-stimulating agents
MB07133 gets orphan drug status

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Acupuncture
Related Content
Complete responses were numerically higher without significance in standard triple antiemetic therapy with olanzapine vs placebo.

Adding Olanzapine to Antiemetic Therapy May Help With CINV Incidence

Roman Fabbricatore
August 4th 2024
Article

Complete responses were numerically higher without significance in standard triple antiemetic therapy with olanzapine vs placebo.

Margaret Rosenzweig, PhD, CRNP-C, AOCNP, FAAN, discusses how nursling-led palliative care may improve advanced cancer care planning uptake based on a secondary analysis of the CONNECT study.

Oncology On-The-Go Podcast: Nursing-Led Palliative Care in Advanced Cancer

Margaret Rosenzweig, PhD, CRNP-C, AOCNP, FAAN
May 15th 2023
Podcast

Margaret Rosenzweig, PhD, CRNP-C, AOCNP, FAAN, discusses how nursling-led palliative care may improve advanced cancer care planning uptake based on a secondary analysis of the CONNECT study.

Incorporating nursing-led palliative care may help to improve advanced care planning among those with advanced cancer, especially those without access to specialty palliative care.

Nursing-Led Palliative Cancer Care May Improve Advanced Care Planning

Hayley Virgil
April 13th 2023
Article

Incorporating nursing-led palliative care may help to improve advanced care planning among those with advanced cancer, especially those without access to specialty palliative care.

Oncology Peer Review On-The-Go: Cancer-Related Fatigue Outcome Measures in Integrative Oncology

Oncology Peer Review On-The-Go: Cancer-Related Fatigue Outcome Measures in Integrative Oncology

Dori Beeler, PhD;Xin Shelley Wang, MD, MPH;Viraj A. Master, MD, PhD
September 20th 2022
Podcast

Authors Dori Beeler, PhD; Shelley Wang, MD, MPH; and Viraj A. Master, MD, PhD, spoke with CancerNetwork® about a review article on cancer-related fatigue published in the journal ONCOLOGY®.

Initial Data on Palliative 177Lu-FAP-2286 Highlights High Uptake and Prolonged Retention Across Several Adenocarcinomas

Initial Data on Palliative 177Lu-FAP-2286 Highlights High Uptake and Prolonged Retention Across Several Adenocarcinomas

Matthew Fowler
August 24th 2021
Article

Positive preliminary data on FAP-2286 linked to the radionuclide lutetium-177 across a diverse array of adenocarcinomas was reported from the phase 1/2 LuMIERE trial.

Qualitative Study Shares Strategies for Successful End of Life Conversations for Patients With Cancer

Qualitative Study Shares Strategies for Successful End of Life Conversations for Patients With Cancer

Ariana Pelosci
August 6th 2021
Article

Trends towards missing key moments for end-of-life discussions when meeting with patients who have stage IV cancer can be overcome with existing strategies for successful EOL conversations.